Preference Based Randomized Trial for Evaluation of Four Treatment Modalities in Prostate Cancer With Low or "Early Intermediate" Risk
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Prostate Cancer
- Sponsor
- Association of Urologic Oncology (AUO)
- Enrollment
- 457
- Locations
- 1
- Primary Endpoint
- Prostate cancer-specific survival
- Status
- Terminated
- Last Updated
- 5 years ago
Overview
Brief Summary
4arms preference based Study to compare four therapy options in prostate cancer with low or early intermediate risk
Detailed Description
The study will compare four possible therapy options for treatment of newly diagnosed prostate cancer with low or "early intermediate" risk according to the patients preferences. The Following hypotheses will be tested: * Radiation is not relevantly worse compared to prostatectomy with regard to time to prostate cancer-related deaths * Permanent seed implantation therapy not inferior to prostatectomy with regard to time to prostate cancer-related deaths. * Active Surveillance does not lead to a significant decrease of time to prostate cancer-related deaths compared to prostatectomy. That for patients with newly diagnosed prostate cancer will be randomized into one of the four treatment arms. Randomization may be limited to at least two of the four treatment arms if a patient refuses one or two of the four treatment arms according to his own preference.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Newly diagnosed, biopsy proven adenocarcinoma of the prostate (ultrasound guided biopsy by standardized protocol)
- •Men aged 18-75 years
- •Recruitment within 3 months after histological confirmation
- •Localized prostata cancer \<= cT2a, NX or N0 M0
- •PSA \<= 10 ng / ml
- •Gleason score \<= 7a (3 +4)
- •ECOG performance status 0 or 1
- •\<= 30% positive biopsy cores with largest contiguous tumor length \<= 5 mm
- •IPSS score \< 18
- •Urine flow (Qmax):\> 15 ml / s
Exclusion Criteria
- •Unifocal Gleason 6 cancer \<1mm
- •History of treatment for BPH e.g. TURP, HIFU or cryotherapy
- •History of radiation therapy to the pelvis
- •Life expectancy \<10 years
- •ASA \>= 4
- •Post-void residual urine \> 50 ml
- •Prostate volume on transrectal ultrasound \> 60 cm3
- •large median prostate lobe visualized on transrectal ultrasound
- •chronic intestinal inflammatory disease covering the rectum
- •Other active malignancy within the past 5 years (except for superficial basal cell carcinoma or non muscle infiltrating bladder carcinoma)
Outcomes
Primary Outcomes
Prostate cancer-specific survival
Time Frame: minimal observation time of 13 years for last study patient
Secondary Outcomes
- - Complications / Safety(median 15 years)
- - Occurrence of the first progression on hormone therapy(17 years)
- - Quality of life on EORTC-QLQ-C30 with additional modul PCA (EORTCQLQ- PR25) as well as HADS-D at baseline(before and 3 Mon. after therapy as well as after 1, 2, 3, 5, 7, 10 and 13 years)
- - Overall survival(minimal observation time of 13 years for last study patient)
- - Time to onset of hormone therapy(17 years)